Given that dysregulation and hyperactivation of the mTOR pathway are for the most part responsible for the pathophysiology of TSC, mTOR inhibitors were introduced for the treatment of various manifestations of TSC. The gene discussed is MTOR; the disease is tuberous sclerosis.